Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder that has been associated with aberrant microbiota. This review focuses on the recent molecular insights generated by analysing the intestinal microbiota in subjects suffering from IBS. Special emphasis is given to studies that compare and contrast the microbiota of healthy subjects with that of IBS patients classified into different subgroups based on their predominant bowel pattern as defined by the Rome criteria. The current data available from a limited number of patients do not reveal pronounced and reproducible IBS-related deviations of entire phylogenetic or functional microbial groups, but rather support the concept that IBS patients have alterations in the proportions of commensals with interrelated changes in the metabolic output and overall microbial ecology. The lack of apparent similarities in the taxonomy of microbiota in IBS patients may partially arise from the fact that the applied molecular methods, the nature and location of IBS subjects, and the statistical power of the studies have varied considerably. Most recent advances, especially the finding that several uncharacterized phylotypes show non-random segregation between healthy and IBS subjects, indicate the possibility of discovering bacteria specific for IBS. Moreover, tools are being developed for the functional analysis of the relationship between the intestinal microbiota and IBS. These approaches may be instrumental in the evaluation of the ecological dysbiosis hypothesis in the gut ecosystem. Finally, we discuss the future outlook for research avenues and candidate microbial biomarkers that may eventually be used in IBS diagnosis.
AerssensJ.,
CamilleriM.,
TalloenW.,
ThielemansL.,
GöhlmannH. W.,
Van Den WyngaertI.,
ThielemansT.,
De HoogtR.,
AndrewsC. N.other authors2008; Alterations in mucosal immunity identified in the colon of patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 6:194–205
CarrollI. M.,
KekuT. O.,
Ringel-KulkaT.,
SartorR. B.,
RingelY.2010; Molecular characterization of the fecal and mucosal-associated intestinal microbiota in patients with diarrhea-predominant IBS and healthy subjects. Gastroenterology 138 (Suppl. 1):S624
ChadwickV. S.,
ChenW.,
ShuD.,
PaulusB.,
BethwaiteP.,
TieA.,
WilsonI.2002; Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology 122:1778–1783
CodlingC.,
O'MahonyL.,
ShanahanF.,
QuigleyE. M.,
MarchesiJ. R.2010; A molecular analysis of fecal and mucosal bacterial communities in irritable bowel syndrome. Dig Dis Sci 55:392–397
DrossmanD. A.,
CorazziariE.,
TalleyN. J.,
ThompsonW. G.,
WhiteheadW. E.2000; The functional GI disorders and the Rome II process. In Rome II. The Functional Gastrointestinal Disorders, 2nd edn. pp 1–30 Edited by
DrossmanD. A.
McLean, VA: Degnon Associates;
DuncanS. H.,
LouisP.,
ThomsonJ. M.,
FlintH. J.2009; The role of pH in determining the species composition of the human colonic microbiota. Environ Microbiol 11:2112–2122
EngelbrektsonA.,
KorzenikJ. R.,
PittlerA.,
SandersM. E.,
KlaenhammerT. R.,
LeyerG.,
KittsC. L.2009; Probiotics to minimize the disruption of faecal microbiota in healthy subjects undergoing antibiotic therapy. J Med Microbiol 58:663–670
FleissnerC. K.,
HuebelN.,
Abd El-BaryM. M.,
LohG.,
KlausS.,
BlautM.2010; Absence of intestinal microbiota does not protect mice from diet-induced obesity. Br J Nutr 5:1–11
FrankD. N.,
St AmandA. L.,
FeldmanR. A.,
BoedekerE. C.,
HarpazN.,
PaceN. R.2007; Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci U S A 104:13780–13785
KarantanosT.,
MarkoutsakiT.,
GazouliM.,
AnagnouN. P.,
KaramanolisD. G.2010; Current insights in to the pathophysiology of irritable bowel syndrome. Gut Pathog 2:3
KerckhoffsA. P.,
SamsomM.,
van der RestM. E.,
de VogelJ.,
KnolJ.,
Ben-AmorK.,
AkkermansL. M.2009; Lower bifidobacteria counts in both duodenal mucosa-associated and fecal microbiota in irritable bowel syndrome patients. World J Gastroenterol 15:2887–2892
KhorutsA.,
DicksvedJ.,
JanssonJ. K.,
SadowskyM. J.2010; Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent Clostridium difficile-associated diarrhea. J Clin Gastroenterol 44:354–360
LouisP.,
ScottK. P.,
DuncanS. H.,
FlintH. J.2007; Understanding the effects of diet on bacterial metabolism in the large intestine. J Appl Microbiol 102:1197–1208
LouisP.,
YoungP.,
HoltropG.,
FlintH. J.2010; Diversity of human colonic butyrate-producing bacteria revealed by analysis of the butyryl-CoA : acetate CoA-transferase gene. Environ Microbiol 12:304–314
MalinenE.,
RinttiläT.,
KajanderK.,
MättöJ.,
KassinenA.,
KrogiusL.,
SaarelaM.,
KorpelaR.,
PalvaA.2005; Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. Am J Gastroenterol 100:373–382
MalinenE.,
Krogius-KurikkaL.,
LyraA.,
NikkiläJ.,
JääskeläinenA.,
RinttiläT.,
Vilpponen-SalmelaT.,
von WrightA.,
PalvaA.2010; Association of symptoms with gastrointestinal microbiota in irritable bowel syndrome. WJG (in press)
MättöJ.,
MaunukselaL.,
KajanderK.,
PalvaA.,
KorpelaR.,
KassinenA.,
SaarelaM.2005; Composition and temporal stability of gastrointestinal microbiota in irritable bowel syndrome – a longitudinal study in IBS and control subjects. FEMS Immunol Med Microbiol 43:213–222
MaukonenJ.,
SatokariR.,
MättöJ.,
SöderlundH.,
Mattila-SandholmT.,
SaarelaM.2006; Prevalence and temporal stability of selected clostridial groups in irritable bowel syndrome in relation to predominant faecal bacteria. J Med Microbiol 55:625–633
MoayyediP.,
FordA. C.,
TalleyN. J.,
CremoniniF.,
Foxx-OrensteinA. E.,
BrandtL. J.,
QuigleyE. M. M.2010; The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut 59:325–332
NakamuraN.,
LinH. C.,
McSweeneyC. S.,
MackieR. I.,
GaskinsH. R.2010; Mechanisms of microbial hydrogen disposal in the human colon and implications for health and disease. Annu Rev Food Sci Technol 1:363–395
ParkesG. C.,
BrostoffJ.,
WhelanK.,
SandersonJ. D.2008; Gastrointestinal microbiota in irritable bowel syndrome: their role in its pathogenesis and treatment. Am J Gastroenterol 103:1557–1567
PimentelM.,
LinH. C.,
EnayatiP.,
van den BurgB.,
LeeH. R.,
ChenJ. H.,
ParkS.,
KongY.,
ConklinJ.2006; Methane, a gas produced by enteric bacteria, slows intestinal transit and augments small intestinal contractile activity. Am J Physiol Gastrointest Liver Physiol 290:G1089–G1095
QinJ.,
LiR.,
RaesJ.,
ArumugamM.,
BurgdorfK. S.,
ManichanhC.,
NielsenT.,
PonsN.,
LevenezF.other authors2010; A human gut microbial gene catalogue established by metagenomic sequencing. Nature 464:59–65
QuigleyE. M. M.2009; Review: do patients with functional gastrointestinal disorders have an altered gut flora?. Therapeutic Advances in Gastroenterology 2 (Suppl. 4):s23–s30
Rajilić-StojanovićM.2007; Diversity of the human gastrointestinal microbiota – novel perspectives from high throughput analyses. PhD thesis University of Wageningen; The Netherlands:
RanaS. V.,
SharmaS.,
SinhaS. K.,
KaurH.,
SikanderA.,
SinghK.2009; Incidence of predominant methanogenic flora in irritable bowel syndrome patients and apparently healthy controls from north India. Dig Dis Sci 54:132–135
ScanlanP. D.,
ShanahanF.,
MarchesiJ. R.2008; Human methanogen diversity and incidence in healthy and diseased colonic groups using mcrA gene analysis. BMC Microbiol 8:79
SchoepferA. M.,
SchafferT.,
Seibold-SchmidB.,
MullerS.,
SeiboldF.2008; Antibodies to flagellin indicate reactivity to bacterial antigens in IBS patients. Neurogastroenterol Motil 20:1110–1118
SwidsinskiA.,
WeberJ.,
Loening-BauckeV.,
HaleL. P.,
LochsH.2005; Spatial organization and composition of the mucosal flora in patients with inflammatory bowel disease. J Clin Microbiol 43:3380–3389
TanaC.,
UmesakiY.,
ImaokaA.,
HandaT.,
KanazawaM.,
FukudoS.2010; Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome. Neurogastroenterol Motil 22:512–519
VanhoutvinS. A.,
TroostF. J.,
KilkensT. O.,
LindseyP. J.,
HamerH. M.,
JonkersD. M.,
VenemaK.,
BrummerR. J.2009; The effects of butyrate enemas on visceral perception in healthy volunteers. Neurogastroenterol Motil 21:952–e76
ZhangH.,
DibaiseJ. K.,
ZuccoloA.,
KudrnaD.,
BraidottiM.,
YuY.,
ParameswaranP.,
CrowellM. D.,
WingR.other authors2009; Human gut microbiota in obesity and after gastric bypass. Proc Natl Acad Sci U S A 106:2365–2370
ZoetendalE. G.,
Rajilić-StojanovićM.,
de VosW. M.2008; High-throughput diversity and functionality analysis of the gastrointestinal tract microbiota. Gut 57:1605–1615